A Study of Indinavir Plus Ritonavir Plus Two NRTIs vs. Nelfinavir Plus Two NRTIs in HIV Positive Patients (0639-112)(COMPLETED)

• Status: Completed
• Trial end date: 2003-05-01
• Target enrollment: 0
• Participant gender: All

Summary

A study comparing Indinavir plus Ritonavir plus 2 NRTIs vs. Nelfinavir 1250 plus two nucleoside reverse transcriptase inhibitors (NRTIs) in the treatment of HIV positive patients who have not responded to or are intolerant to a non-nucleoside reverse transcriptase inhibitor (NNRTI) containing treatment.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Merck Sharp & Dohme Corp.
• Treatments: Indinavir; Nelfinavir; Ritonavir

Criteria

Inclusion Criteria:

• At least 18 years of age

• HIV positive

• No active heart disease

Exclusion Criteria:

• Pregnant or breast feeding

• Unwilling to use birth control or abstinence to prevent pregnancy

• Received an investigational drug or vaccine within the past 30 days or is planning to receive other investigational study drug/vaccine or interferon while in the study

• Plan to receive NNRTIs while in the study

• Received therapy which lowers body's ability to fight infection within the past 30 days or while in the study

• Alcohol or substance abuse

• Hepatitis